TrialSignal
Clinical trial intelligence report
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00785785
Status
COMPLETED
Phase
Phase III
Sponsor
Novartis Pharmaceuticals
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the efficacy and safety of nilotinib compared to imatinib in adult patients with unresectable or metastatic GIST. Conducted by Novartis, the study involved 644 participants across multiple sites and aimed to determine the time to progression-free survival (PFS) as the primary outcome.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00785785
Indication
Gastrointestinal Stromal Tumor (GIST)
Modality
small molecule
Target
Gastrointestinal Stromal Tumors (GIST)
Intervention
Nilotinib (AMN107), imatinib (STI571)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.